Macrogenics (MGNX) EBIT (2012 - 2026)
Macrogenics (MGNX) posted quarterly EBIT of -$33.4 million for Q1 2026, up 21.55% year-over-year from -$27.5 million in Q1 2025, and down 176.42% quarter-over-quarter from -$12.1 million in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) EBIT (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported EBIT for 15 consecutive years, with -$33.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 21.55% year-over-year to -$33.4 million; the TTM figure through Mar 2026 stood at -$63.7 million (up 35.99% YoY), while the FY2025 annual figure was -$72.8 million, up 34.13% from the prior year.
- EBIT eased to -$33.4 million in Q1 2026 per MGNX's latest filing, from -$12.1 million in the prior quarter.
- Across five years, EBIT topped out at $54.2 million in Q3 2024 and bottomed at -$66.6 million in Q1 2022.
- Historically, EBIT has averaged -$29.8 million across 5 years, with a median of -$38.4 million in 2023.
- Annual changes were most pronounced in 2023 — EBIT plunged 511.87% — and 2024, when it soared 252.64%.
- Macrogenics' EBIT stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then slipped by 7.06% to -$52.8 million in 2024, then jumped by 77.11% to -$12.1 million in 2025, then slumped by 176.42% to -$33.4 million in 2026.
- Business Quant data shows MGNX's EBIT at -$33.4 million in Q1 2026, -$12.1 million in Q4 2025, and $18.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Macrogenics | 274.73 Mn | 160.82 Mn | - | -13.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.85 Mn |
| Mar 31, 2026 | -33.44 Mn |
| Dec 31, 2025 | -12.10 Mn |
| Sep 30, 2025 | 18.64 Mn |
| Jun 30, 2025 | -43.22 Mn |
| Mar 31, 2025 | -42.62 Mn |
| Dec 31, 2024 | -52.84 Mn |
| Sep 30, 2024 | 54.19 Mn |
| Jun 30, 2024 | -58.18 Mn |
| Mar 31, 2024 | -53.75 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -44.96 Mn |
| Mar 31, 2023 | -38.43 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -66.64 Mn |
| Dec 31, 2021 | -58.24 Mn |
| Sep 30, 2021 | -52.99 Mn |